Twenty-eight patients affected by advanced non-small cell lung cancer (NSCLC) were enrolled in a feasibility study evaluating toxicity and activity of carboplatin-vindesine combination chemotherapy, according to two different schedules. Fourteen patients were treated with carboplatin 350 mg/m2 monthly and vindesine 3 mg/m2 weekly for 5 doses, then every other week (schedule 1). The activity observed was promising with 3 partial remissions, but the toxicity was substantial, preventing full dose administration in 11 out of 14 patients. The subsequent 14 patients were treated with carboplatin 350 mg/m2 monthly and vindesine 3 mg/m2 on days 1 and 8 of each cycle. Activity was maintained with 4 partial remissions and toxicity was quite tolerable, allowing all patients to receive the planned treatment. The combination of carboplatin 350 mg/m2 on day 1 and vindesine 3 mg/m2 on days 1 and 8 seems active and well tolerated in advanced NSCLC patients and deserves further evaluation in a larger phase II study.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/1120009x.1992.11739151 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncology.
Int J Clin Oncol
November 2024
Department of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, Gifu, 501-1194, Japan.
Article Synopsis
- Chemotherapy-induced nausea and vomiting (CINV) negatively impacts patient quality of life, leading to a study that evaluated the effectiveness of adding neurokinin-1 receptor antagonists (NK1RAs) to existing antiemetic treatments for patients undergoing moderately emetogenic chemotherapy (MEC).
- A systematic review of clinical studies identified 15 randomized controlled trials involving over 4,400 patients, revealing that triplet antiemetic regimens including NK1RAs significantly improved complete response and complete control of nausea compared to doublet regimens, without increasing adverse events.
- While the addition of NK1RA shows promise for enhancing antiemetic efficacy in carboplatin-based chemotherapy, further research is needed
Effectiveness of treatment of oropharyngeal carcinoma patients.
Wiad Lek
September 2024
DNIPRO STATE MEDICAL UNIVERSITY, DNIPRO, UKRAINE.
Objective: Aim: To analyze the results of treatment of patients with oropharyngeal carcinoma.
Patients And Methods: Materials and Methods: 276 patients with oropharyngeal carcinoma were treated in 2008-2021. Neoadjuvant chemotherapy consisted of three to six cycles: paclitaxel 175 mg/m2 and carboplatin 350 mg/m2 (or cisplatin 100 mg/m2) on the first day.
The Novel Platinum Analog Dicycloplatin Provides Reliable Growth Inhibition of Urothelial Carcinoma Cells .
Anticancer Res
August 2024
Department of Urology, West Virginia University School of Medicine, Morgantown, WV, U.S.A.
Article Synopsis
- Dicycloplatin (DCP) shows better solubility and tolerability compared to traditional platinum-based chemotherapies like cisplatin and carboplatin, making it a promising candidate for treating urothelial carcinoma (UC), particularly non-muscle-invasive bladder cancer.
- In vitro studies exposed high-grade UC cell lines to varying concentrations of DCP, cisplatin, and carboplatin, demonstrating that all effectively achieved over 90% cell kill after 72 hours, with DCP's efficacy increasing with concentration and exposure time.
- Overall, the findings support the potential use of DCP in intravenous, oral, and intravesical therapies for bladder UC, indicating its effectiveness in neoadjuvant and adjuvant treatment
Neoadjuvant inetetamab and pertuzumab with taxanes and carboplatin (TCbIP) In locally advanced HER2-positive breast cancer: a prospective cohort study with propensity-matched analysis.
BMC Cancer
July 2024
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Background: Inetetamab is the first domestically developed innovative anti-HER2 monoclonal antibody in China, proven effective and safe in HER2-positive advanced breast cancer. However, its efficacy and safety in neoadjuvant treatment of HER2-positive locally advanced breast cancer (LABC) remain to be validated.
Methods: This prospective cohort study aimed to evaluate the efficacy and safety of inetetamab combined with pertuzumab, taxanes, and carboplatin (TCbIP) in neoadjuvant therapy for HER2-positive LABC, comparing it to data from patients treated with the TCbHP regimen (trastuzumab combined with pertuzumab, taxanes, and carboplatin) using propensity score matching (PSM).
Introduction: Atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) combination therapy is a standard of care for advanced non-squamous non-small cell lung cancer (NSQ-NSCLC); however, the lack of safety data limits its clinical application in Japan.
Methods: This study compared the safety of ABCP with that of bevacizumab, carboplatin, and paclitaxel (BCP) combination for the treatment of advanced NSQ-NSCLC in Japanese patients by evaluating the clinical background and incidence of adverse events (AEs) based on data extracted from the Diagnosis Procedure Combination (DPC) database. Incidence rates and restricted mean survival times (RMSTs) for up to 1 year were analyzed for 19 clinically important AEs.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!